https://neurosciencenews.com/pembrolizumad-immunotherapy-brain-cancer-23387/
0
0
6/2/23 at 9:13pm
Organization
Neurosciencenews.com
Author
Neuroscience News
36 words
0
Comments
A phase 2 clinical trial of pembrolizumab has shown promising results, with 42% of patients with metastatic brain cancer benefiting from the treatment.
You are the first to view
Create an account
or login to join the discussion